





PATENT Attorney Docket No. 056291-5225

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Confirmation No.: 9414		
	Eva-Lotte LINDSTEDT-ALSTERMARK et al.)			
)	Group Art Unit: 1625		
Application No.: 10/561,126					
		·)	Examiner: Unassigned		
Filed:	December 16, 2005)			
)			
For:	THERAPEUTIC AGENTS)	Date: September 19, 2006		

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT

<u>UNDER 37 C.F.R. § 1.97(b)</u>

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents (U.S. Patents) are not attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed

Attorney Docket No.: 056291-5225 Application No. 10/561,126

Page 2

invention over the listed documents, should one or more of the documents be applied against the claims of

the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by

this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockin's LLP

Date:

September 19, 2006

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By: Donald J. Bird

Registration No. 25,323 Tel. No.: (202) 739-5320

Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION				Attorney Docket No. 056291-5225		Application No. 10/561,126				
l	(Us	se several sheets if nece	essetty PE 40	Applicants: Eva-Lotte LINDSTEDT-ALSTERMARK et al.						
PTO Form 1449 SEP 1 9 2006 September 19, 2004			Filing Date: December 16, 2005		Group Art Unit: 1625					
PTO Form 1449 SEP 1 9 2006 Filing Date: December 16, 2005 Group Art Unit: 1625										
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date			
	1.	US 6,630,600	October 7, 2003	Andersson et al.	560	55	July 20, 1999			
	2.	US 6,258,850	July 10, 2001	Andersson	514	571	July 20, 1999			
					1					
			FOREIGN	PATENT DOCUMENTS						
	T 7	Document No.	Date	Country	Class	Sub-Class	Translation			
	<u> </u>		<u> </u>							
		OTHER DO	OCUMENTS (Include	ding Author, Title, Date, Per	rtinent Pa	ges, etc.)				
						B				
	<u> </u>									
	<u> '</u>	<u> </u>								
	<u> </u> '									
<u> </u>										
	├ ──'	 								
										
	+						<u> </u>			
	\vdash									
	<u> </u>	<u> </u>								
	<u> </u>									
	 	 								
	 	 								
	\vdash	 				<u>_</u>				
 !										
Examiner	لــــــا	<u> </u>	Date C	Considered						
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

. 10 W